

HIV Protease/RT Resistance Genotype Report

NRTI

Lamivudine	Potential Low-Level Resistance
Abacavir	Low-Level Resistance
Zidovudine	Susceptible
Stavudine	Low-Level Resistance
Didanosine	Low-Level Resistance
Emtricitabine	Potential Low-Level Resistance
Tenofovir	Low-Level Resistance

The genotyping assay was developed and its performance characteristics determined by the testing laboratory. The sequence results were generated by the testing laboratory, and sequence interpretations performed via an automated service at the BC Centre for Excellence in HIV/AIDS. The BC Centre cannot be held responsible for the quality, integrity and correctness of the sequence results, or for the correctness of the patient demographic data added to this report. For US clients, this report has not been cleared or approved by the U.S. Food and Drug Administration. Interpretation is done by Stanford HIV Web Service Sierra, of phenotypic change for protease/RT sequences. Please see <http://hivdb.stanford.edu/pages/webservices/> for further information.